POPULARITY
14 episodes with clinical oncology asco
18 episodes with clinical oncology asco
9 episodes with clinical oncology asco
11 episodes with clinical oncology asco
6 episodes with clinical oncology asco
7 episodes with clinical oncology asco
6 episodes with clinical oncology asco
10 episodes with clinical oncology asco
8 episodes with clinical oncology asco
7 episodes with clinical oncology asco
6 episodes with clinical oncology asco
8 episodes with clinical oncology asco
8 episodes with clinical oncology asco
6 episodes with clinical oncology asco
3 episodes with clinical oncology asco
7 episodes with clinical oncology asco
6 episodes with clinical oncology asco
5 episodes with clinical oncology asco
3 episodes with clinical oncology asco
4 episodes with clinical oncology asco
3 episodes with clinical oncology asco
2 episodes with clinical oncology asco
3 episodes with clinical oncology asco
2 episodes with clinical oncology asco
8 episodes with clinical oncology asco
4 episodes with clinical oncology asco
2 episodes with clinical oncology asco
Dr. Tania Small joined Bristol Myers Squibb as Senior Vice President, Global Medical Affairs in January 2024. Tania brings a strong scientific track record leading Medical Affairs teams in driving innovation that improves the experience and supports better outcomes of people living with cancer and rare diseases. She has successfully built and led global and regional medical organizations in Drug Development and Medical Affairs, advancing access to Oncology, Rare Disease and Hematology patients globally.Tania is a board-certified pediatric hematology, oncology, and bone marrow transplant specialist with deep experience in clinical research and drug development. She has extensive research experience in oncology, hematology, gene therapy and stem cell transplantation, receiving NIH grants for her translational research in gene therapy and regenerative medicine.Most recently, Tania served as Head of Global Medical Oncology and was the sponsor of the Global R&D Inclusion Diversity Council at GSK. Prior to GSK, Tania worked for IPSEN as Vice President, Head of Oncology and Rare Disease Global Drug Development.She is energized by revolutionizing the experience and outcomes for people with cancer, and has worked closely with the US FDA, Congress, and the American Society of Clinical Oncology (ASCO) to improve the diversity of enrollment in oncology clinical trials and elderly programs."I'm passionate about partnering to create programs that treat the person - not just the disease. Producing groundbreaking solutions that can change the trajectory of serious diseases and help write the next chapter of patient-driven science is what motivates me every day."Tania received her medical degree from Albert Einstein College of Medicine. She has a long-standing affiliation with the Morgan Stanley Children's Hospital of New York Presbyterian/Columbia University where she completed her residency and hematology/oncology fellowship with an academic research appointment in heme and bone marrow transplant.Currently, Tania serves on the ASCO Membership Advisory Committee and is a Board Member of Accreditation Council for Medical Affairs (ACMA).
Oncologist burnout and career dissatisfaction are a “huge problem,” says Robin T. Zon, MD, president of the American Society of Clinical Oncology (ASCO). Dr. Zon sits down with Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer Center in Los Angeles, to discuss revelations from a recent ASCO report. “ASCO recognizes that if, in fact, we are going to accomplish our mission, we have to pay very close attention to what is happening to the workforce and the burnout that is associated with that,” Dr. Zon explains. She shares insights into common underlying causes and lays out a plan of attack for improvement. With an emphasis primarily on organizational, and not individual, reforms, Dr. Zon pledges that ASCO will remain focused on burnout and job dissatisfaction. “We are going to continue to have interventions. And we will continue to give voice to our members at all levels.” Dr. Zon reported various financial relationships. Dr. Figlin reported various financial relationships.
Be sure to tune in to this episode of the Precision Health and PGX Podcast as Dr. Becky Winslow, and Dr. Angela Cassano, PharmFusion Founder and owner, discuss Dr. Cassano's personal pharmacogenomics testing and how the results impacted her breast cancer treatment, the tamoxifen and CYP2D6 pharmacogenomics clinical utility research currently available, whether CYP2D6 testing for patients prior to tamoxifen is National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO) recommended, and whether insurers in the United States reimburse the testing. This is a must listen for those interested in the clinical pharmacogenomics' current landscape and a pharmacist-patient's perspective about PGx testing. Â
Be sure to tune in to this episode of the Precision Health and PGX Podcast as Dr. Becky Winslow, and Dr. Angela Cassano, PharmFusion Founder and owner, discuss Dr. Cassano's personal pharmacogenomics testing and how the results impacted her breast cancer treatment, the tamoxifen and CYP2D6 pharmacogenomics clinical utility research currently available, whether CYP2D6 testing for patients prior to tamoxifen is National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO) recommended, and whether insurers in the United States reimburse the testing. This is a must listen for those interested in the clinical pharmacogenomics' current landscape and a pharmacist-patient's perspective about PGx testing. Â
In this episode, Ayesha spoke with Mario Marcondes, MD, PhD, VP Head of Clinical Development at Nektar Therapeutics, a company focused on the discovery and development of novel therapies for autoimmune disorders and cancer. Dr. Marcondes is a licensed and trained physician, specializing in oncology and immune oncology. He has more than 15 years of research and teaching experience in Bone Marrow Transplant (BMT)/Cellular Therapies and more than 10 years of industry experience. He was the Program Lead for early-stage assets at Nektar and manages clinical trial programs from Phase I through to Phase III. Dr. Marcondes is a member of multiple professional clinical and translational research organizations, including the American Society of Clinical Oncology (ASCO), American Society of Hematology (ASH), American Association for Cancer Research (AACR) and Center for International Blood & Marrow Transplant Research (CIBMTR). Listen to the episode to hear about the current research landscape in autoimmune disorders, including the work Dr. Marcondes is leading at Nektar Therapeutics. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured
In this enlightening episode of The Patient From Hell podcast, Dr. Doug Blayney and host Samira Daswani dive deep into the key insights from the 2024 San Antonio Breast Cancer Symposium (SABCS). They explore four critical areas of breast cancer care: CDK4/6 inhibitors, antibody-drug conjugates (ADCs), de-escalation strategies for ductal carcinoma in situ (DCIS), and the emerging role of artificial intelligence in cancer diagnostics. Throughout the conversation, a central theme emerges: the increasing ability to personalize cancer treatment, considering individual patient characteristics, biological markers, treatment options, and personal goals for quality and quantity of life. Key Highlights: 1. Biomarkers are becoming increasingly sophisticated, allowing for more precise and personalized treatment approaches across different breast cancer subtypes. 2. Patient choice and individual considerations are paramount, with treatment decisions now focusing on balancing potential survival benefits against quality of life impacts. 3. Emerging technologies like antibody-drug conjugates and artificial intelligence are revolutionizing breast cancer care by offering more nuanced, targeted diagnostic and treatment options. About our guest: Dr. Doug Blayney is an oncology physician who specializes in breast cancer and the Chief Medical Officer of Manta Cares. His research focuses on quality improvement in cancer care systems, new drug development, and patient experience improvement. At the American Society of Clinical Oncology (ASCO), he was founding Editor-in-Chief of its flagship practice journal, and as President, started the ASCO Quality Symposium and began planning for ASCO's CancerLinq. He was a founding member of the National Comprehensive Cancer Network (NCCN) Growth Factor Guideline panel, and is a past member of the U.S. Food and Drug Administration's Oncology Drugs Advisory Committee and the NCCN Board of Directors. Key Moments: At 38 minutes: "There's a company now that has a gene expression panel that may predict, and it looks like it does predict, whether radiation treatment after standard treatment for DCIS is beneficial. So if this predicted biomarker of benefit for radiation pans out, and I think it probably will, that means that we can deescalate or personalize whether radiation treatment and its side effects are likely to be beneficial to that patient." At 45 minutes: "Quality of life, can that be answered by a nine question questionnaire? Well, maybe. If you can't get out of bed, your quality of life is because something hurts or if your arm doesn't work because they're so swollen, that's one extreme... What about 15 years playing that duet? What about three? It's those kind of subtleties that we need to take into account." At 49 minutes:"AI can interpret mammograms. The images from a mammogram 20 years ago, there were four, top, bottom, side, side, and maybe another oblique. And now there's 60 images from a mammogram. So that means that a radiologist, a human radiologist, whether it's next door or around the world, somebody needs to look at those. AI can help." Disclaimer: All content and information provided in connection with Manta Cares is solely intended for informational and educational purposes only. This content and information is not intended to be a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
- Overview of ASCO's 2024 Theme – “The Art and Science of Cancer Care from Comfort to Cure” - Specific Updates on the Treatment of Colorectal Cancer Presented at ASCO - Quality-of-Life Issues: Managing Treatment Side Effects, Symptoms, Discomfort & Pain - Specific Updates on the Treatment of Pancreas Cancer Presented at ASCO - The Role of Supportive Care - Specific Updates on the Treatment of Lymphoma Presented at ASCO - The Important Role of Clinical Trials: How Research Increases Treatment Options - Specific Updates on the Treatment of Leukemia Presented at ASCO - Communicating with Your Health Care Team: Key Questions to Ask - Specific Updates on the Treatment of Melanoma Presented at ASCO - Concluding Wrap-Up of Part II
- Overview of ASCO's 2024 Theme – “The Art and Science of Cancer Care from Comfort to Cure” - Specific Updates on the Treatment of Colorectal Cancer Presented at ASCO - Quality-of-Life Issues: Managing Treatment Side Effects, Symptoms, Discomfort & Pain - Specific Updates on the Treatment of Pancreas Cancer Presented at ASCO - The Role of Supportive Care - Specific Updates on the Treatment of Lymphoma Presented at ASCO - The Important Role of Clinical Trials: How Research Increases Treatment Options - Specific Updates on the Treatment of Leukemia Presented at ASCO - Communicating with Your Health Care Team: Key Questions to Ask - Specific Updates on the Treatment of Melanoma Presented at ASCO - Concluding Wrap-Up of Part II
- Overview of ASCO's 2024 Theme – “The Art and Science of Cancer Care from Comfort to Cure” - Specific Updates on the Treatment of Colorectal Cancer Presented at ASCO - Quality-of-Life Issues: Managing Treatment Side Effects, Symptoms, Discomfort & Pain - Specific Updates on the Treatment of Pancreas Cancer Presented at ASCO - The Role of Supportive Care - Specific Updates on the Treatment of Lymphoma Presented at ASCO - The Important Role of Clinical Trials: How Research Increases Treatment Options - Specific Updates on the Treatment of Leukemia Presented at ASCO - Communicating with Your Health Care Team: Key Questions to Ask - Specific Updates on the Treatment of Melanoma Presented at ASCO - Concluding Wrap-Up of Part II
- Overview of ASCO's 2024 Theme – “The Art and Science of Cancer Care from Comfort to Cure” - Specific Updates on the Treatment of Colorectal Cancer Presented at ASCO - Quality-of-Life Issues: Managing Treatment Side Effects, Symptoms, Discomfort & Pain - Specific Updates on the Treatment of Pancreas Cancer Presented at ASCO - The Role of Supportive Care - Specific Updates on the Treatment of Lymphoma Presented at ASCO - The Important Role of Clinical Trials: How Research Increases Treatment Options - Specific Updates on the Treatment of Leukemia Presented at ASCO - Communicating with Your Health Care Team: Key Questions to Ask - Specific Updates on the Treatment of Melanoma Presented at ASCO - Concluding Wrap-Up of Part II
- Overview of ASCO's 2024 Theme – “The Art and Science of Cancer Care from Comfort to Cure” - Specific Updates on the Treatment of Colorectal Cancer Presented at ASCO - Quality-of-Life Issues: Managing Treatment Side Effects, Symptoms, Discomfort & Pain - Specific Updates on the Treatment of Pancreas Cancer Presented at ASCO - The Role of Supportive Care - Specific Updates on the Treatment of Lymphoma Presented at ASCO - The Important Role of Clinical Trials: How Research Increases Treatment Options - Specific Updates on the Treatment of Leukemia Presented at ASCO - Communicating with Your Health Care Team: Key Questions to Ask - Specific Updates on the Treatment of Melanoma Presented at ASCO - Concluding Wrap-Up of Part II
- Overview of ASCO's 2024 Theme – “The Art and Science of Cancer Care from Comfort to Cure” - Specific Updates on the Treatment of Colorectal Cancer Presented at ASCO - Quality-of-Life Issues: Managing Treatment Side Effects, Symptoms, Discomfort & Pain - Specific Updates on the Treatment of Pancreas Cancer Presented at ASCO - The Role of Supportive Care - Specific Updates on the Treatment of Lymphoma Presented at ASCO - The Important Role of Clinical Trials: How Research Increases Treatment Options - Specific Updates on the Treatment of Leukemia Presented at ASCO - Communicating with Your Health Care Team: Key Questions to Ask - Specific Updates on the Treatment of Melanoma Presented at ASCO - Concluding Wrap-Up of Part II
Triple Negative Breast Cancer CancerCare Connect Education Workshops
- 2024 American Society of Clinical Oncology (ASCO) Annual Meeting: Triple Negative Breast Cancer Updates - New Research on Triple Negative Breast Cancer Presented at ASCO - Triple Negative Breast Cancer-Specific Treatment Updates - Updates on Clinical Trials in Advancing Treatment Choices - The Increasing Role of Diagnostic Testing, Biomarkers & Genetic Testing in Informing Treatment Options - Investigational New Therapies in Clinical Trials - New Developments in the Prevention & Management of Treatment Side Effects, Symptoms, Discomfort & Pain - Communicating with the Health Care Team with Telehealth/Telemedicine Appointments - Guidelines for Preparing for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, Adherence, Follow-Up Care & Discussion of OpenNotes - Questions to Ask Our Panel of Experts
- 2024 American Society of Clinical Oncology (ASCO) Annual Meeting: Triple Negative Breast Cancer Updates - New Research on Triple Negative Breast Cancer Presented at ASCO - Triple Negative Breast Cancer-Specific Treatment Updates - Updates on Clinical Trials in Advancing Treatment Choices - The Increasing Role of Diagnostic Testing, Biomarkers & Genetic Testing in Informing Treatment Options - Investigational New Therapies in Clinical Trials - New Developments in the Prevention & Management of Treatment Side Effects, Symptoms, Discomfort & Pain - Communicating with the Health Care Team with Telehealth/Telemedicine Appointments - Guidelines for Preparing for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, Adherence, Follow-Up Care & Discussion of OpenNotes - Questions to Ask Our Panel of Experts
- 2024 American Society of Clinical Oncology (ASCO) Annual Meeting: Triple Negative Breast Cancer Updates - New Research on Triple Negative Breast Cancer Presented at ASCO - Triple Negative Breast Cancer-Specific Treatment Updates - Updates on Clinical Trials in Advancing Treatment Choices - The Increasing Role of Diagnostic Testing, Biomarkers & Genetic Testing in Informing Treatment Options - Investigational New Therapies in Clinical Trials - New Developments in the Prevention & Management of Treatment Side Effects, Symptoms, Discomfort & Pain - Communicating with the Health Care Team with Telehealth/Telemedicine Appointments - Guidelines for Preparing for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, Adherence, Follow-Up Care & Discussion of OpenNotes - Questions to Ask Our Panel of Experts
Featuring a slide presentation and related discussion from Dr Priyanka Sharma, including the following topics: Biomarker Assays in the Identification and Prognostication of Patients with Breast Cancer (0:00) Utility of Circulating Tumor DNA in the Prognostication of Localized Breast Cancer (24:28) Treatment of HR-Positive, HER2-Negative Advanced Breast Cancer with a PI3K Mutation (29:46) Utility of Subsequent CDK4/6 Inhibitor After Disease Progression on Initial Therapy (34:57) Treatment of HER2-Low or HER2-Ultralow Metastatic Breast Cancer (40:59) Updated Data and Novel Strategies Involving Trastuzumab Deruxtecan for the Treatment of Advanced Breast Cancer (49:42) Oral Selective Estrogen Receptor Degraders for the Treatment of ER-Positive, HER2-Positive Breast Cancer (51:55) Novel Strategies Involving Antibody-Drug Conjugates and Immunotherapy for Triple-Negative Breast Cancer (58:12) CME information and select publications
Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, discusses recent advances in the treatment of breast cancer following the 2024 ASCO Annual Meeting.
Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, discusses recent advances in the treatment of breast cancer following the 2024 ASCO Annual Meeting, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayPostASCO24/BreastCancer).
Ziad Bakouny, MD, MSc, and Nazli Dizman, MD, return to the show to discuss the progress made for International Medical Graduates (IMGs) within the American Society of Clinical Oncology (ASCO). Building on their previous conversation, they explore the origins of their initiatives at ASCO 2022, the goals for integrating IMGs into successful medical careers in the US, and the significant challenges posed by Visa constraints. Together, they expand on the unique hurdles faced by IMGs in oncology, how these compare across specialties, and the ongoing efforts to support IMGs. Check out Chadi's website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA
- Overview of ASCO's 2024 Theme – The Art and Science of Cancer from Comfort to Cure - Updates on the Treatment of Breast Cancer Presented at ASCO - Updates on the Treatment of Ovarian Cancer Presented at ASCO - The Role of Clinical Trials: How Research Increases Treatment Options - Updates on the Treatment of Prostate Cancer Presented at ASCO - Talking with Your Health Care Team about Your Treatment Choices - Updates on the Treatment of Brain Cancer Presented at ASCO - Quality-of-Life Concerns - Updates on the Treatment of Oral, Head and Neck Cancer Presented at ASCO - Management of Treatment Side Effects, Symptoms, Discomfort & Pain - Updates on the Treatment of Sarcoma Presented at ASCO - Wrap-Up of Part I of ASCO 2024
- Overview of ASCO's 2024 Theme – The Art and Science of Cancer from Comfort to Cure - Updates on the Treatment of Breast Cancer Presented at ASCO - Updates on the Treatment of Ovarian Cancer Presented at ASCO - The Role of Clinical Trials: How Research Increases Treatment Options - Updates on the Treatment of Prostate Cancer Presented at ASCO - Talking with Your Health Care Team about Your Treatment Choices - Updates on the Treatment of Brain Cancer Presented at ASCO - Quality-of-Life Concerns - Updates on the Treatment of Oral, Head and Neck Cancer Presented at ASCO - Management of Treatment Side Effects, Symptoms, Discomfort & Pain - Updates on the Treatment of Sarcoma Presented at ASCO - Wrap-Up of Part I of ASCO 2024
- Overview of ASCO's 2024 Theme – The Art and Science of Cancer from Comfort to Cure - Updates on the Treatment of Breast Cancer Presented at ASCO - Updates on the Treatment of Ovarian Cancer Presented at ASCO - The Role of Clinical Trials: How Research Increases Treatment Options - Updates on the Treatment of Prostate Cancer Presented at ASCO - Talking with Your Health Care Team about Your Treatment Choices - Updates on the Treatment of Brain Cancer Presented at ASCO - Quality-of-Life Concerns - Updates on the Treatment of Oral, Head and Neck Cancer Presented at ASCO - Management of Treatment Side Effects, Symptoms, Discomfort & Pain - Updates on the Treatment of Sarcoma Presented at ASCO - Wrap-Up of Part I of ASCO 2024
- Overview of ASCO's 2024 Theme – The Art and Science of Cancer from Comfort to Cure - Updates on the Treatment of Breast Cancer Presented at ASCO - Updates on the Treatment of Ovarian Cancer Presented at ASCO - The Role of Clinical Trials: How Research Increases Treatment Options - Updates on the Treatment of Prostate Cancer Presented at ASCO - Talking with Your Health Care Team about Your Treatment Choices - Updates on the Treatment of Brain Cancer Presented at ASCO - Quality-of-Life Concerns - Updates on the Treatment of Oral, Head and Neck Cancer Presented at ASCO - Management of Treatment Side Effects, Symptoms, Discomfort & Pain - Updates on the Treatment of Sarcoma Presented at ASCO - Wrap-Up of Part I of ASCO 2024
- Overview of ASCO's 2024 Theme – The Art and Science of Cancer from Comfort to Cure - Updates on the Treatment of Breast Cancer Presented at ASCO - Updates on the Treatment of Ovarian Cancer Presented at ASCO - The Role of Clinical Trials: How Research Increases Treatment Options - Updates on the Treatment of Prostate Cancer Presented at ASCO - Talking with Your Health Care Team about Your Treatment Choices - Updates on the Treatment of Brain Cancer Presented at ASCO - Quality-of-Life Concerns - Updates on the Treatment of Oral, Head and Neck Cancer Presented at ASCO - Management of Treatment Side Effects, Symptoms, Discomfort & Pain - Updates on the Treatment of Sarcoma Presented at ASCO - Wrap-Up of Part I of ASCO 2024
Host: Saad Z. Usmani, MD, MBA, FACP Guest: Joshua Richter, MD Guest: Ashley Steinberger, APP Release date: 8/15/2024Expiration date: 8/15/2025Estimated time to complete: 1.0 hour This activity is not accredited for CME/CE credit. This episode of Myeloma Matters reviews the latest data on bispecific antibody therapy for relapsed/refractory multiple myeloma (RRMM) discussed at the 2024 American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings, including information about the use of fixed-duration dosing to mitigate adverse events (AEs). The program includes in-depth discussion and analysis of the latest scientific findings and practice-changing advances in managing RRMM. Expert faculty will place abstract findings into clinical context and discuss strategies for preventing and managing AEs associated with bispecific antibody therapy in RRMM treatment, which include cytokine release syndrome (CRS), neurotoxicity, and infection.
- Overview of ASCO's 2024 Theme – The Art and Science of Cancer from Comfort to Cure - Updates on the Treatment of Breast Cancer Presented at ASCO - Updates on the Treatment of Ovarian Cancer Presented at ASCO - The Role of Clinical Trials: How Research Increases Treatment Options - Updates on the Treatment of Prostate Cancer Presented at ASCO - Talking with Your Health Care Team about Your Treatment Choices - Updates on the Treatment of Brain Cancer Presented at ASCO - Quality-of-Life Concerns - Updates on the Treatment of Oral, Head and Neck Cancer Presented at ASCO - Management of Treatment Side Effects, Symptoms, Discomfort & Pain - Updates on the Treatment of Sarcoma Presented at ASCO - Wrap-Up of Part I of ASCO 2024
In this episode, Dr. Doug Blayney, oncologist, former President of the American Society of Clinical Oncology (ASCO), and the Chief Medical Officer of Manta Cares, discusses the latest advancements in breast cancer treatments presented at ASCO's 2024 Annual Meeting. He highlights the significant progress in antibody drug conjugates (ADCs), which are engineered to specifically target cancer cells, offering new hope in cancer treatment. The Manta Cares team also attended the ASCO conference, presenting an abstract for a personal treatment management tool designed to assist cancer patients and survivors (and their families!) in navigating their next steps – Manta Maps! For more information, visit our website here and join the list to request access to the digital platform this fall here. Key Highlights: 1. Advancements in breast cancer treatment were highlighted at the ASCO Annual Meeting this year, including alternatives to chemotherapy and the emergence of antibody drug conjugates (ADCs). 2. Checkpoint inhibitors help the immune system recognize and attack cancer cells by removing the "brakes" that prevent the immune system from targeting the cancer. 3. Personalized approaches to treatment based on patient age, co-morbidities, and cancer type, were highlighted, leading to more effective and tailored treatments. About our guest: Dr. Doug Blayney is an oncology physician who specializes in breast cancer. His research focuses on quality improvement in cancer care systems, new drug development, and patient experience improvement. At the American Society of Clinical Oncology (ASCO), he was founding Editor-in-Chief of its flagship practice journal, and as President, started the ASCO Quality Symposium and began planning for ASCO's CancerLinq. He was a founding member of the National Comprehensive Cancer Network (NCCN) Growth Factor Guideline panel, and is a past member of the U.S. Food and Drug Administration's Oncology Drugs Advisory Committee and the NCCN Board of Directors. Dr. Blayney leads the Manta Cares Scientific Advisory Board as the Chief Medical Officer. Key Moments: At 1:05 "As a doctor who treats breast cancer, I thought it was important that we have a lot of alternatives to chemotherapy. So even though some of the studies were portrayed as negative because they didn't improve overall survival, I think pushing out the time a patient gets chemotherapy and its associated toxicities is a major advance.” At 21:14 "We need better assays to predict who's going to respond to these ADCs (Antibody Drug Conjugates). We're learning that they're here to stay and they're a great benefit to many with breast cancer and other cancers." At 35:20 “It's thought that you and people without known cancer, develop one or two cancers a day, small little bitty ones and our body's immune system recognizes that as foreign and eats them up and the cancer doesn't grow and proliferate. One of the ways cancer grows, especially in adults, is immune escape. So somehow the brakes are put on the immune system at some point when that cancer develops. The IO checkpoint inhibitors are thought to work by taking off those brakes.” Visit the Manta Cares website Disclaimer: This podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user's own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard, or delay in obtaining, medical advice for any medical condition they may have, and should seek the assistance of their health care professionals for any such conditions. --- Support this podcast: https://podcasters.spotify.com/pod/show/manta-cares/support
This installment of Oncology Data Advisor's Exploring Artificial Intelligence (AI) in Oncology series features a discussion recorded live at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting between Ranjana Devi, Vice President of Product Development, Oncology, at Qure.ai, and Fellows Forum member Dr. Waqas Haque. Check out the episode to hear more about: • Qure.ai's mission of making healthcare more accessible and equitable to patients worldwide through innovations in deep learning and AI • Current challenges in lung cancer screening and the capabilities of AI in addressing these gaps • Qure.ai's end-to-end AI-powered solutions for early lung cancer detection and care • The efficacy of these solutions and how they can be used in the clinic • The lung cancer portfolio that Qure.ai showcased at ASCO • Other innovations coming down the pipeline • And more!
This playlist features interviews recorded live by Oncology Data Advisor at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago. Visit oncdata.com to learn more!
This playlist features interviews recorded live by Oncology Data Advisor at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago. Visit oncdata.com to learn more!
This playlist features interviews recorded live by Oncology Data Advisor at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago. Visit oncdata.com to learn more!
This playlist features interviews recorded live by Oncology Data Advisor at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago. Visit oncdata.com to learn more!
This playlist features interviews recorded live by Oncology Data Advisor at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago. Visit oncdata.com to learn more!
This playlist features interviews recorded live by Oncology Data Advisor at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago. Visit oncdata.com to learn more!
This playlist features interviews recorded live by Oncology Data Advisor at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago. Visit oncdata.com to learn more!
This playlist features interviews recorded live by Oncology Data Advisor at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago. Visit oncdata.com to learn more!
This playlist features interviews recorded live by Oncology Data Advisor at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago. Visit oncdata.com to learn more!
This playlist features interviews recorded live by Oncology Data Advisor at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago. Visit oncdata.com to learn more!
This playlist features interviews recorded live by Oncology Data Advisor at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago. Visit oncdata.com to learn more!
This playlist features interviews recorded live by Oncology Data Advisor at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago. Visit oncdata.com to learn more!
Drs. Claudine Isaacs and Filipa Lynce discuss highlights of the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, with a focus on HER2+ breast cancer, including late-breaking abstracts such as DESTINY‑Breast06 and others.
Each June, the American Society of Clinical Oncology (ASCO) hosts a conference that gathers physicians, researchers and the cancer community to share their latest research on treatments, technologies and more. The Fierce team is always on the ground at the ASCO meeting, and this year, Fierce Biotech's Gabrielle Masson and Fierce Pharma's Angus Liu covered the event. In this week's episode of "The Top Line," they discuss the most talked-about data drops at ASCO and share on-the-ground details, including their experience with Gilead's virtual reality Trodelvy ride. To learn more about the topics in this episode: Akeso, Summit's Keytruda win draws 'explosive' interest at ASCO. But what does Merck think? ASCO: After Keytruda, Merck builds 3-pronged cancer strategy starring Moderna-partnered vaccine ASCO: Cautious Big Pharmas double down on past wins—steering clear of radioligands and cell therapy See omnystudio.com/listener for privacy information.
A snub by an FDA advisory committee for an MDMA-psychotherapy combination is unlikely to read through to other psychedelic therapies in the pipeline. On the BioCentury This Week podcast, BioCentury's editors discuss the shortcomings of the Lykos Therapeutics product's clinical development program and why other psychedelics likely won't face the same hurdles. The editors also assess FDA's new platform technology designation and the first-in-human clinical trials described at this year's American Society of Clinical Oncology (ASCO) meeting. This week's podcast is sponsored by Nxera Pharma.00:01 - Sponsor Message: Nxera Pharma01:41 - Psychedelic Setback12:38 - FDA's Platform Play21:39 - ASCO Innovations
Conference season kicked into high gear this week with the American Society of Clinical Oncology (ASCO) annual meeting in Chicago and the BIO International Convention in San Diego. Check out BioSpace's ASCO24 Tracker with all the biggest data and other news from the cancer meeting, which wrapped up on Tuesday. Among the trial results highlighted at ASCO24 were BMS' Phase III study results in liver cancer. There was also a lot of news on non-small cell lung cancer (NSCLC): Pfizer presented results from a Phase III trial evaluating its ALK inhibitor Lorbrena, BMS provided three updates on its immunotherapy Opdivo and Opdivo-based combinations, while Gilead unveiled additional details on a failed Phase III trial for its antibody-drug conjugate (ADC) Trodelvy. Currently, there is one ADC approved to treat NSCLC, AstraZeneca and Daiichi Sankyo's Enhertu, for patients with HER2-mutated metastatic disease. While the companies' investigational ADC Dato-DXd is making some headway against NSCLC, experts recently told BioSpace that more compelling surface targets for lung cancer are needed in order for ADCs to really make a difference. When it comes to M&A, Big Pharma continues to show strong interest in oncology, particularly ADCs and radiopharmaceuticals. However, last week's biggest deal was Merck's $3 billion acquisition of EyeBio and its first-in-class trispecific antibody Restoret, marking the company's return to the ophthalmology space after nearly a decade. For now, it appears Big Pharma favors smaller M&A over megabillion-dollar deals. Recent buying activity also indicates a potential resurgence in the appetites of larger companies for psychiatric drug development.
Chris Barden, a co-managing partner at MPM Bioimpact who manages the firm's Bioimpact Equities and Oncology Impact funds, shares her insights into the upcoming American Society of Clinical Oncology (ASCO) conference in Chicago. She talks about the major trends in oncology, including development of antibody drug conjugates, which is currently the hottest area in cancer treatment. Another highlight she expects from ASCO will be development in radiotherapy treatments, particularly in prostate cancer. Bardon provides a guide for attendees to use in setting their schedules for the year's biggest cancer conference and what to watch for in the future.
At its Investor Day 2024 event last week, AstraZeneca announced plans to reach $80 billion in total revenue by 2030—up from $45.8 billion in 2023—and to launch 20 new medicines by the end of the decade. Does AstraZeneca have the assets and developmental pipeline to hit this lofty target? Meanwhile, Bayer, BMS and Pfizer are looking to conserve cash through cost-savings plans that include layoffs. It's a trend we'll be keeping a close eye on as companies face potential implications from upcoming patent expirations, the Inflation Reduction Act's Drug Price Negotiation Program and investor expectations. On the R&D front, Takeda took a deep dive into the hot molecular glue degrader space, signing a potential $1.2 billion exclusive licensing deal with China-based Degron Therapeutics. The new partners will be going after various oncology, neuroscience and inflammatory disease targets. Takeda follows Novo Nordisk, Roche's Genentech and Merck, who have all recently struck R&D deals focused on molecular glues degraders. And the conference season again kicks into high gear this weekend with the American Society of Clinical Oncology (ASCO)'s annual meeting starting Friday in Chicago and the 2024 BIO International Convention beginning Monday in San Diego. BioSpace's Heather McKenzie will be moderating a BIO panel focused on closing the gaps in neuropsychiatric drug development, so if you're heading to San Diego, please pop in and say hello!
While there is undeniable hope for the future of cancer care, systemic barriers still impact access for many patients – particularly those in underserved communities. This session, originally recorded in front of a live audience at SXSW 2024, examines how increasing collaboration and partnerships among organizations that touch all aspects of the cancer journey and reach patients, providers and treatment centers, is critical to expanding access to optimal cancer care and making the goals of the “Cancer Moonshot” a reality. Hear from City of Hope, American Society of Clinical Oncology (ASCO), and American Cancer Society (ACS) about how they are approaching partnerships to create a future where every cancer patient has access to the care they need.Â
This Conversations in MF podcast will discuss the most clinically relevant data and emerging strategies into practice to improve outcomes for patients with MF presented from the 2023 international meetings of the American Society of Clinical Oncology (ASCO), European Hematology Association (EHA) and Society of Hematologic Oncology (SOHO).Launch Date: January 29, 2024Release Date: January 29, 2024Expiration Date: December 30, 2024FACULTY BIOSPrithviraj Bose, MDProfessor, Department of Leukemia, Division of Cancer MedicineUniversity of TexasMD Anderson Cancer CenterJohn Mascarenhas, MDProfessor of MedicineIcahn School of Medicine at Mount SinaiDirector, Center of Excellence in Blood Cancers and Myeloid DisordersRuben Mesa, MDExecutive DirectorAtrium Health Wake Forest Baptist Comprehensive Cancer CenterThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/conference-briefs-highlighting-myelofibrosis-clinical-data-from-key-conferences-17
This Conversations in MF podcast will discuss the most clinically relevant data and emerging strategies into practice to improve outcomes for patients with MF presented from the 2023 international meetings of the American Society of Clinical Oncology (ASCO), European Hematology Association (EHA) and Society of Hematologic Oncology (SOHO).Launch Date: January 29, 2024Release Date: January 29, 2024Expiration Date: December 30, 2024FACULTY BIOSPrithviraj Bose, MDProfessor, Department of Leukemia, Division of Cancer MedicineUniversity of TexasMD Anderson Cancer CenterJohn Mascarenhas, MDProfessor of MedicineIcahn School of Medicine at Mount SinaiDirector, Center of Excellence in Blood Cancers and Myeloid DisordersRuben Mesa, MDExecutive DirectorAtrium Health Wake Forest Baptist Comprehensive Cancer CenterThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/conference-briefs-highlighting-myelofibrosis-clinical-data-from-key-conferences-17
This Conversations in MF podcast will discuss the most clinically relevant data and emerging strategies into practice to improve outcomes for patients with MF presented from the 2023 international meetings of the American Society of Clinical Oncology (ASCO), European Hematology Association (EHA) and Society of Hematologic Oncology (SOHO).Launch Date: January 29, 2024Release Date: January 29, 2024Expiration Date: December 30, 2024FACULTY BIOSPrithviraj Bose, MDProfessor, Department of Leukemia, Division of Cancer MedicineUniversity of TexasMD Anderson Cancer CenterJohn Mascarenhas, MDProfessor of MedicineIcahn School of Medicine at Mount SinaiDirector, Center of Excellence in Blood Cancers and Myeloid DisordersRuben Mesa, MDExecutive DirectorAtrium Health Wake Forest Baptist Comprehensive Cancer CenterThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/conference-briefs-highlighting-myelofibrosis-clinical-data-from-key-conferences-17
© 2020-2025 Ivy Podcast Discovery LLC
